Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in 2025 and 2026.

Members of the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) group along with experienced ...

In December 2024, the National Comprehensive Cancer Network® (NCCN) added AUCATZYL (obecabtagene autoleucel) to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the treatment of ...

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...

Baseline factors linked to SLE flares during pregnancy included thrombocytopenia and a history of LN, while antimalarial therapy demonstrated protective effects.

Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Mar. 12, 2025 — Lupus is an autoimmune disease where the body's immune system attacks its own tissues and organs, causing inflammation and damaging organs. A new study has now shown that the ...

Patients receiving ICIs were associated with a greater risk of developing RA, but lower risks for SLE and SSc.

Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according ...

A new study finds that ChatGPT4 provides answers to lupus patient questions as effectively as rheumatologists, excelling in ...

Lupus is an autoimmune disease where the body's immune system attacks its own tissues and organs, causing inflammation and damaging organs. A new study has now shown that the natural active ingredient ...